Toll-like receptors, endogenous ligands, and systemic autoimmune disease

被引:320
作者
Rifkin, IR
Leadbetter, EA
Busconi, L
Viglianti, G
Marshak-Rothstein, A
机构
[1] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Med, Renal Sect, Boston, MA 02118 USA
[3] Harvard Univ, Sch Med, BWH, Div Rheumatol Allergy & Immunol, Boston, MA USA
关键词
D O I
10.1111/j.0105-2896.2005.00239.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The critical role of Toll-like receptors (TLRs) as mediators of pathogen recognition by the innate immune system is now firmly established. Such recognition results in the initiation of an inflammatory immune response and subsequent instruction of the adaptive immune system, both of which are designed to rid the host of the invading pathogen. More controversial is the potential role of TLRs in the recognition of endogenous ligands and what effect this might have on the consequent development of autoimmune or other chronic sterile inflammatory disorders. An increasing number of studies implicate TLRs as being involved in the immune response to self-molecules that have in some way been altered from their native state or accumulate in non-physiologic sites or amounts, although questions have been raised about possible contaminants in certain of these studies. In this review, we discuss the evidence for endogenous ligand-TLR interactions with particular emphasis on mammalian chromatin, systemic lupus erythematosus, and atherosclerosis. Overall, the data support the general concept of a role for TLRs in the recognition of endogenous ligands. However, the precise details of the interactions and the extent to which they may contribute to the pathogenesis of human disease remain to be clarified.
引用
收藏
页码:27 / 42
页数:16
相关论文
共 146 条
[61]   Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells [J].
Kalergis, AM ;
Ravetch, JV .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (12) :1653-1659
[62]   mRNA is an endogenous ligand for Toll-like receptor 3 [J].
Karikó, K ;
Ni, HP ;
Capodici, J ;
Lamphier, M ;
Weissman, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) :12542-12550
[63]   Unresponsiveness of MyD88-deficient mice to endotoxin [J].
Kawai, T ;
Adachi, O ;
Ogawa, T ;
Takeda, K ;
Akira, S .
IMMUNITY, 1999, 11 (01) :115-122
[64]   Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes [J].
Kench, JA ;
Russell, DM ;
Nemazee, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (05) :909-917
[65]   Toll-like receptor 4 polymorphisms and atherogenesis [J].
Kiechl, S ;
Lorenz, E ;
Reindl, M ;
Wiedermann, CJ ;
Oberhollenzer, F ;
Bonora, E ;
Willeit, J ;
Schwartz, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (03) :185-192
[66]   I-PLA2 activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin m antibodies and complement activation [J].
Kim, SJ ;
Gershov, D ;
Ma, XJ ;
Brot, N ;
Elkon, KB .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (05) :655-665
[67]   Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice [J].
Kirii, H ;
Niwa, T ;
Yamada, Y ;
Wada, H ;
Saito, K ;
Iwakura, Y ;
Asano, M ;
Moriwaki, H ;
Seishima, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (04) :656-660
[68]   Cutting edge:: Innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells [J].
Koski, GK ;
Karikó, K ;
Xu, SW ;
Weissman, D ;
Cohen, PA ;
Czerniecki, B .
JOURNAL OF IMMUNOLOGY, 2004, 172 (07) :3989-3993
[69]   Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs [J].
Krieg, AM ;
Wu, T ;
Weeratna, R ;
Efler, SM ;
Love-Homan, L ;
Yang, L ;
Yi, AK ;
Short, D ;
Davis, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) :12631-12636
[70]  
Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO